01177.HK
Sino Biopharmaceutical Limited
HKSE · Healthcare · Biotechnology · HK
HKD 4.85
−0.10%Year over year
Reported trailing growth
- Revenue
- +10.3%
- EBITDA
- +74.0%
- EBIT
- +63.1%
- EPS
- -38.5%
- Free cash flow
- +78.7%
- Operating cash flow
- +94.0%
Forward estimates
Based on analyst estimates
- Revenue
- +50.0%
- EBITDA
- -10.6%
- EPS
- +170.5%
Three-year CAGR
- Revenue
- +6.9%
- EBITDA
- +3.9%
- EBIT
- +7.6%
- Net income
- -2.7%
- EPS
- +5.7%
- Free cash flow
- +18.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026